Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Top Cited Papers
- 21 June 2007
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (25), 2582-2590
- https://doi.org/10.1056/nejmoa070389
Abstract
Smoldering (asymptomatic) multiple myeloma is an asymptomatic plasma-cell proliferative disorder associated with a high risk of progression to symptomatic multiple myeloma or amyloidosis. Prognostic factors for the progression and outcome of this disease are unclear.Keywords
This publication has 20 references indexed in Scilit:
- Thalidomide as initial therapy for early-stage myelomaLeukemia, 2003
- Review of 1027 Patients With Newly Diagnosed Multiple MyelomaMayo Clinic Proceedings, 2003
- Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AMLThe Hematology Journal, 2003
- Prognostic Factors for Malignant Transformation in Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple MyelomaJournal of Clinical Oncology, 2002
- A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined SignificanceNew England Journal of Medicine, 2002
- Prognostic factors in low tumour mass asymptomatic multiple myeloma: A report on 91 patientsAmerican Journal of Hematology, 1995
- Prognosis of asymptomatic multiple myelomaArchives of Internal Medicine, 1988
- Smoldering Multiple MyelomaNew England Journal of Medicine, 1980
- Asymptotically Efficient Rank Invariant Test ProceduresJournal of the Royal Statistical Society. Series A (General), 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958